



Republic of the Philippines  
Department of Health

## CENTRAL OFFICE BIDS AND AWARDS COMMITTEE

COBAC RESOLUTION NO. 2020-030-B  
25 November 2020

### RECOMMENDING APPROVAL OF THE AWARD OF CONTRACT THROUGH REPEAT FOR THE PROCUREMENT OF LAMIVUDINE + TENOFOVIR + EFAVIRENZ TABLET RO NO. 2020- 003

WHEREAS, the Central Office Bids and Awards Committee (COBAC) – A received the request from the Disease Prevention and Control Bureau (DPCB) – National HIV/AIDS and STI Prevention and Control Program (NASPCP) for the Procurement of Lamivudine + Tenofovir + Efavirenz Tablet in accordance with the Republic Act (RA) 9184 and its 2016 Revised Implementing Rules and Regulations (IRR) through the General Appropriations Act of 2020 with a Total Approved Budget for the Contract (ABC) of *Ninety Million Seventy-Nine Thousand Three Hundred Seventy-One Philippine Pesos (Php90,079,371.00): /*

Item No.	Item Description	Qty	Unit	Total ABC (Php)
1	Lamivudine + Tenofovir + Efavirenz /	164,079 /	Bottle /	90,079,371.00 /

WHEREAS, COBAC Resolution No. 2020-030 “Recommending Approval of the Award of Contract for the Procurement of Lamivudine + Tenofovir + Efavirenz Tablet under IB No. 2020-015” has been approved;

WHEREAS, COBAC Resolution No. 2020-030-A “Recommending Approval for the Use of an Alternative Method through Repeat Order for Lamivudine + Tenofovir + Efavirenz Tablet,” has been approved; ,

WHEREAS, the approved Contract No. GOP-C-2020-017 and Notice to Proceed (NTP) were issued L. Meyerf Pharma Inc. (LMPf) to wit: /

Item Description	Original Qty.	Unit Cost (Php)	Awarded Contract (Php)	Issuance of PO and NTP
Lamivudine + Tenofovir + Efavirenz /	965,170 Bottles /	549.00 /	529,878,330.00 /	25 June 2020

WHEREAS, the Technical Working Group (TWG) was created through the issuance of Department Personnel Order (DPO) COBAC No. 2020-336 dated 09 November 2020;

WHEREAS, on 09 November 2020, COBAC – A issued an invitation to LMPf requesting to submit quotation for the Repeat Order;

WHEREAS, on 16 November 2020, LMPf submitted its quotation which was considered within the prescribed timeline given that 10 and 11 November 2020 (Thursday and Friday) was suspended due to typhoon Ulysses, to wit;

Item No.	Particular	Quantity for Repeat	ABC (Php)		Price Quotation (Php)	
			Unit Cost	Total Cost	Unit Cost (Php)	Total Cost
1	Lamivudine + Tenofovir + Efavirenz	164,079 bottles	549.00	90,079,371.00	549.00	90,079,371.00

WHEREAS, the same date, the cited proposal was forwarded to the TWG, for evaluation;

WHEREAS, on 17 November 2020, the TWG –Legal and Technical Evaluators found LMPI compliant with the legal and financial aspect of their bid and submitted their evaluation report;

WHEREAS, on 24 November 2020, the TWG –Technical Evaluator found LMPI compliant with the technical aspect of their bid and submitted its evaluation report;/


WHEREAS, on 25 November 2020, upon presentation of the evaluation report, the COBAC-A during its 46<sup>th</sup> Regular Meeting concurred with the TWG and recommended the award of contract in favor of LMPI;

NOW THEREFORE, in consideration of the above premises, the herein members of the COBAC-A HEREBY RESOLVE to recommend the award of contract to L. Meyer Pharma Inc. (LMP) with a Total Contract Price of **Ninety Million Seventy Nine Thousand Three Hundred Seventy One Philippine Pesos (PhP90,079,371.00)** inclusive of taxes for the item listed below:

Item No.	Item Description	Qty.	Unit	Unit Cost	Total Amount (PhP)
1	Lamivudine + Tenofovir + Efavirenz /	164,079 /	Bottle /	549.00 /	90,079,371.00 /


Signed this day of DEC 04 <sup>2020</sup> at the Department of Health, San Lazaro Compound, Sta. Cruz, Manila.

**CENTRAL OFFICE BIDS AND AWARDS COMMITTEE (COBAC) - A**

  
ALELI ANNE GRACE P. SUDIACAL, MD, MPH, CESE  
Regular Member


  
LEONTA P. GORGOLON, MD, MHA, MCHM, CEO VI  
Regular Member

  
MARIA SOLEDAD Q. ANTONIO, MD, PhD, MPH, DPAFP, CESE  
Vice-Chairperson

  
LESTER M. TAN, MD, MPH, MSc  
Regular Member

**NESTOR F. SANTIAGO, JR., MD, MPH, MSA, CESO II**  
Assistant Secretary of Health  
Chairperson

By Authority of the Secretary of Health:

  
MYRNA C. CABOTAJE, MD, MPH, CESO III  
Undersecretary of Health  
Public Health Service Team (PHST)

DEC 29 2023